Electrolyte Blood Press.  2014 Dec;12(2):41-54. 10.5049/EBP.2014.12.2.41.

How do We Manage Coronary Artery Disease in Patients with CKD and ESRD?

• Choi HY
• Park HC
• Ha SK

• KMID: 2052331
• DOI: http://doi.org/10.5049/EBP.2014.12.2.41

Abstract

Chronic kidney disease (CKD) has been shown to be an independent risk factor for cardiovascular events. In addition, patients with pre-dialysis CKD appear to be more likely to die of heart disease than of kidney disease. CKD accelerates coronary artery atherosclerosis by several mechanisms, notably hypertension and dyslipidemia, both of which are known risk factors for coronary artery disease. In addition, CKD alters calcium and phosphorus homeostasis, resulting in hypercalcemia and vascular calcification, including the coronary arteries. Mortality of patients on long-term dialysis therapy is high, with age-adjusted mortality rates of about 25% annually. Because the majority of deaths are caused by cardiovascular disease, routine cardiac catheterization of new dialysis patients was proposed as a means of improving the identification and treatment of high-risk patients. However, clinicians may be uncomfortable exposing asymptomatic patients to such invasive procedures like cardiac catheterization, thus noninvasive cardiac risk stratification was investigated widely as a more palatable alternative to routine diagnostic catheterization. The effective management of coronary artery disease is of paramount importance in uremic patients. The applicability of diagnostic, preventive, and treatment modalities developed in nonuremic populations to patients with kidney failure cannot necessarily be extrapolated from clinical studies in non-kidney failure populations. Noninvasive diagnostic testing in uremic patients is less accurate than in nonuremic populations. Initial data suggest that dobutamine echocardiography may be the preferred diagnostic method. PCI with stenting is a less favorable alternative to CABG, however, it has a faster recovery time, reduced invasiveness, and no overall mortality difference in nondiabetic and non-CKD patients compared with CABG. CABG is associated with reduced repeat revascularizations, greater relief of angina, and increased long term survival. However, CABG is associated with a higher incidence of post-operative risks. The treatment chosen for each patient should be an individualized decision based upon numerous risk factors. CKD is associated with higher rates of CAD, with 44% of all-cause mortality attributable to cardiac disease and about 20% from acute MI. Optimal treatment including aggressive lifestyle modifications and concomitant medical therapy should be implemented in all patients to maximize benefits from either PCI or CABG. Future prospective randomized controlled trials with newer second or third generation DES and bioabsorbable DES are necessary to determine if PCI may be non-inferior to CABG in the future.

Keyword

Chronic kidney disease; Coronary artery disease

MeSH Terms

Atherosclerosis
Calcium
Cardiac Catheterization
Cardiac Catheters
Cardiovascular Diseases
Catheterization
Catheters
Coronary Artery Disease*
Coronary Vessels
Diagnostic Tests, Routine
Dialysis
Dobutamine
Dyslipidemias
Echocardiography
Heart Diseases
Homeostasis
Humans
Hypercalcemia
Hypertension
Incidence
Kidney Diseases
Kidney Failure, Chronic*
Life Style
Mortality
Phosphorus
Renal Insufficiency
Renal Insufficiency, Chronic
Risk Factors
Stents
Vascular Calcification
Calcium
Dobutamine
Phosphorus

Reference

1. National kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2):suppl 1. s1–s266. PMID: 11904577.

2. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80:17–28. PMID: 21150873.

3. Collins AJ, Foley RN, Herzog C, et al. USRDS 2012 Annual Data Report. Am J Kidney Dis. 2013; 61(1):Suppl 1. e1–e421.

4. Weiner DE, Tighiouart H, Amin MG, et al. Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. J Am Soc Nephrol. 2004; 15:1307–1315. PMID: 15100371.

5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32:S112–S119. PMID: 9820470.

6. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003; 41:47–55. PMID: 12570944.

7. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13:745–753. PMID: 11856780.

8. Cooper WA, O'Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006; 113:1063–1070. PMID: 16490821.

9. Nakano T, Ninomiya T, Sumiyoshi S. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2010; 55:21–30. PMID: 19765871.

10. Chonchol M, Whittle J, Desbien A. Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol. 2008; 28:354–360. PMID: 18046083.

11. Ix JH, Shlipak MG, Liu HH. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol. 2003; 14:3233–3238. PMID: 14638921.

12. Weiner DE, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis. 2006; 48:392–401. PMID: 16931212.

13. Go AS, Chetow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305. PMID: 15385656.

14. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116:85–97. PMID: 17606856.

15. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351:1285–1295. PMID: 15385655.

16. Joki N, Hase H, Nakamura R. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant. 1997; 12:718–723. PMID: 9141000.

17. Ohtake T, Kobayashi S, Moriya H. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005; 16:1141–1148. PMID: 15743997.

18. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002; 106:974–980. PMID: 12186803.

19. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003; 42:1535–1543. PMID: 14607434.

20. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998; 339:799–805. PMID: 9738087.

21. Trespalacios FC, Taylor AJ, Agoda LY, Abbott KC. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002; 62:1799–1805. PMID: 12371982.

22. Longenecker JC, Coresh J, Powe NR. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002; 13:1918–1927. PMID: 12089389.

23. Weiner DE, Tighiouart H, Elsayed EF. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007; 50:217–224. PMID: 17631213.

24. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin Nephrol. 2001; 56:221–230. PMID: 11597037.

25. Kalantar-Zadeh K, Block G, Humphreys MH. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63:793–808. PMID: 12631061.

26. Balla S, Nusair MB, Alpert MA. Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. Curr Opin Pharmacol. 2013; 13:192–199. PMID: 23291030.

27. Muntner P, He J, Astor BC, Foleon AR, Coresh J. Traditional and non-traditional risk factors predicts coronary heart disease is chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol. 2005; 16:529–538. PMID: 15625072.

28. Bhatt DL. Anti-inflammatory agents and antioxidants as a possible 'third great wave' in cardiovascular secondary prevention. Am J Cardiol. 2008; 101:4D–13D.

29. Weiner DE, Tighiouart H, Elsayed EF, et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 2008; 73:1406–1412. PMID: 18401337.

30. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010; 6:261–273. PMID: 20234356.

31. Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxy-vitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008; 168:1174–1180. PMID: 18541825.

32. Kovesdy CP, Ahmadzadeh S, Anderson JE. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008; 168:397–403. PMID: 18299495.

33. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant. 2002; 17:1713–1724. PMID: 12270974.

34. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000; 15:218–223. PMID: 10648668.

35. Herzog CA. Sudden cardiac death and acute myocardial infarction in dialysis patients: perspectives of a cardiolo0 gist. Semin Nephrol. 2005; 25:363–366. PMID: 16298256.

36. Nakano T, Ninomiya T, Sumiyoshi S, et al. Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney Int. 2013; 84:373–380. PMID: 23594677.

37. Kato K, Yonetsu T, Jia H, et al. Non-culprit coronary plaque characteristics of chronic kidney disease. Circ CV Imaging. 2013; 6(3):448–456.

38. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80:572–586. PMID: 21750584.

39. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006; 296:1377–1384. PMID: 16985230.

40. Karthikeyan V, Ananthasubramaniam K. Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation. Curr Cardiol Rev. 2009; 5:177–186. PMID: 20676276.

41. Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation. 2007; 116:1465–1472. PMID: 17785621.

42. Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006; 47:378–384. PMID: 16490615.

43. De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension. 2003; 42:263–268. PMID: 12913060.

44. Lewis MS, Wilson RA, Walker KW, et al. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol. 2002; 89:847–850. PMID: 11909572.

45. Lentine KL, Costa SP, Weir MR, et al. AHA/ACCF/ASTS/AST/NKF 2012 Cardiac disease evaluation and management among kidney and liver transplantation candidates. Circulation. 2012; 126:617–663. PMID: 22753303.

46. Freda BJ, Tang WH, Van LF, et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. 2002; 40:2065–2071. PMID: 12505215.

47. Schmidt A, Stefenelli T, Schuster E, et al. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis. 2001; 37:56–63. PMID: 11136168.

48. Vandenberg BF, Rossen JD, Grover-McKay M, Shammas NW, Burns TL, Rezai K. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation. 1996; 62:1230–1235. PMID: 8932262.

49. Patel AD, Abo-Auda WS, Davis JM, et al. Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation. Am J Cardiol. 2003; 92:146–151. PMID: 12860215.

50. National kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease-CVD. Am J Kidney Dis. 2005; 45(suppl 3):s18–s20.

51. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007; 20:566–569. PMID: 17991206.

52. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006; 70:2021–2030. PMID: 17051142.

53. Shurraw S, Majumdar SR, Thadhani R, et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis. 2010; 55:875–884. PMID: 20346561.

54. Zager PG, Nikolic J, Brown RH, et al. 'U' curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998; 54:561–569. PMID: 9690224.

55. Cooper SP, Hardy RJ, Labarthe DR, et al. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am J Epidemiol. 1988; 127:387–403. PMID: 3276167.

56. Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension. 2010; 55:762–768. PMID: 20083728.

57. Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol. 2006; 17:513–520. PMID: 16396968.

58. National kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49(2):suppl 2. s12–s154. PMID: 17276798.

59. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004; 110:1557–1563. PMID: 15364796.

60. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004; 110:2809–2816. PMID: 15492322.

61. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238–248. PMID: 16034009.

62. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360:1395–1407. PMID: 19332456.

63. Baigent C, Landray MJ, Reith C. on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011; 377:2181–2192. PMID: 21663949.

64. Isbel NM, Haluska B, Johnson DW, et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J. 2006; 151:745–753. PMID: 16504645.

65. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010; 56:956–965. PMID: 20828648.

66. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71–86. PMID: 11786451.

67. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997; 278:2093–2098. PMID: 9403425.

68. Chan MY, Becker RC, Sim LL, et al. Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. Ann Acad Med Singapore. 2010; 39:179–184. PMID: 20372752.

69. Dragu R, Behar S, Sandach A, et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and STelevation acute myocardial infarction. Am J Cardiol. 2006; 97:1142–1155. PMID: 16616015.

70. Medi C, Montalescot G, Budaj A, et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc Interv. 2009; 2:26–33. PMID: 19463394.

71. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a metaanalysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006; 48:1319–1325. PMID: 17010789.

72. Cooper WA, O'Brien SM, Thourani VH, et al. Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006; 113:1063–1070. PMID: 16490821.

73. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009; 120:851–858. PMID: 19704097.

74. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007; 116:2762–2772. PMID: 17998462.

75. King SB III, Smith SC Jr, Hirshfeld JW Jr. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008; 117:261–295. PMID: 18079354.

76. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009; 104:1647–1653. PMID: 19962469.

77. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J. 2005; 149:512–519. PMID: 15864241.

78. Charytan DM, Kuntz RE. Risks of coronary artery bypass surgery in dialysis-dependent patients-analysis of the 2001 National Inpatient Sample. Nephrol Dial Transplant. 2007; 22:1665–1671. PMID: 17299001.

79. Charytan DM, Li S, Liu J, Herzog CA. Risk of death and End-Stage Renal Disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease. Circulation. 2012; 126(suppl 1):s164–s169. PMID: 22965978.

80. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation. 2002; 106:2207–2211. PMID: 12390949.

81. Ishio N, Kobayashi T, Takebayashi H, et al. Impact of drug-eluting stents on clinical and outcomes in dialysis patients. Circ J. 2007; 71:1525–1529. PMID: 17895545.

82. Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation. 2013; 127:1861–1869. PMID: 23572500.